Did You Know?

Editor’s Picks

Latest News

argenx Presents Phase 3 ALKIVIA Data at ACR Convergence 2026 Showing Rapid and Sustained Improvement with Efgartigimod in Autoimmune Myositis

ALKIVIA met its primary and key secondary endpoints in the combined IMNM and DM populationFirst Phase 3 study to demonstrate...

Inimmune Presents Late-Breaking Phase 1 INI-4001 Results Demonstrating On-Target Immune Activation in Advanced Solid Tumors at SITC 2026

Study demonstrated no dose-limiting toxicities and dose-responsive cytokine production consistent with TLR7/8 engagementResults support continued clinical development of INI-4001 as...

error: Content is protected !!